According to systematic reviews and meta-analyses in healthy and clinical non-stroke populations, MBIs may lower cortisol levels, reduce inflammation markers such as C-reactive protein (CRP) and interleukin-6 (IL-6), and enhance immune function, including increased CD4+ T lymphocytes and delayed immune cell aging [42,43,44,45,46,47,48,49,50,51]. The gene discussed is CRP; the disease is stroke disorder.